Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Autoantibody

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    91 result(s) found for: Autoantibody. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2012-000385-38 Sponsor Protocol Number: BEL116472 Start Date*: 2012-05-18
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: BEL116472. A 2 year mechanistic study of belimumab in Idiopathic Membranous Glomerulonephropathy
    Medical condition: Idiopathic Membranous Glomerulonephropathy (IMGN)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001923-30 Sponsor Protocol Number: TN-20 Start Date*: 2016-09-26
    Sponsor Name:TRIALNET COORDINATING CENTER AT THE UNIVERSITY OF SOUTH FLORIDA
    Full Title: Exploring Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus
    Medical condition: Type 1 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10066284 Diabetes prophylaxis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001034-11 Sponsor Protocol Number: CLOU064A2303B Start Date*: 2022-11-28
    Sponsor Name:Novartis Pharma AG
    Full Title: A multicenter, double-blind, placebo-controlled, randomized withdrawal and open-label extension study followed by long-term open-label treatment cycles to assess the efficacy, safety and tolerabili...
    Medical condition: Chronic Spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) SK (Trial now transitioned) DE (Trial now transitioned) AT (Completed) HU (Trial now transitioned) IT (Trial now transitioned) BG (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2020-005732-29 Sponsor Protocol Number: MOM-M281-011 Start Date*: 2021-11-19
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generali...
    Medical condition: Myasthenia gravis (MG).
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000241-21 Sponsor Protocol Number: BEL114870 Start Date*: 2011-06-23
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A clinical and mechanistic proof of efficacy study with belimumab in chronic immune thrombocytopenia (ITP) patients
    Medical condition: Chronic Immune Thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10051057 Idiopathic thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001621-29 Sponsor Protocol Number: 80804002 Start Date*: 2009-05-05
    Sponsor Name:Faculty of Medicine Carl Gustav Carus, University of Technology, Dresden
    Full Title: Pre-POINT (Primary Oral INsulin Trial) study A dose finding safety and immune efficacy study for primary mucosal insulin therapy in islet autoantibody negative children at high genetic risk for ty...
    Medical condition: pre-type 1 diabetes (islet autoimmunity in non-diabetic relatives of subjects with type 1 diabetes)
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001586-87 Sponsor Protocol Number: RSLV-132-04 Start Date*: 2016-09-29
    Sponsor Name:Resolve Therapeutics, LLC
    Full Title: A Phase 2, Double Blind, Placebo Controlled Study of RSLV-132 in Subjects with Primary Sjogren’s Syndrome
    Medical condition: Primary Sjogrens Syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-005287-15 Sponsor Protocol Number: 808040017 Start Date*: 2015-07-15
    Sponsor Name:Technische Universität München, Fakultät für Medizin
    Full Title: - PRE-POINT-EARLY STUDY - Pilot study using oral insulin at early age for immune efficacy in primary prevention of type 1 diabetes
    Medical condition: Risk for type 1 diabetes
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-007484-16 Sponsor Protocol Number: DIAPREV/2008 Start Date*: 2009-02-27
    Sponsor Name:Helena Elding Larsson
    Full Title: DIAPREV-IT Diabetes Prevention Immune Tolerance. A double-blind, randomized investigator-initiated study to determine the safety and the effect of Diamyd® on the progression to type 1 diabetes in ...
    Medical condition: Children with HLA risk and persistent islet autoantibody positivity which is associated with a defined risk for type 1 diabetes
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003379-31 Sponsor Protocol Number: 808040015 Start Date*: 2017-01-31
    Sponsor Name:Technische Universität München, Fakultät für Medizin
    Full Title: An immune efficacy study for primary prevention using intranasal insulin therapy in islet autoantibody negative children at high genetic risk for type 1 diabetes
    Medical condition: Risk for type 1 diabetes
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004374-27 Sponsor Protocol Number: ProPATIent Start Date*: 2006-10-12
    Sponsor Name:Philipps-University
    Full Title: Prospective, randomized, doubleblind, placebo-controlled trial on changes in acetylcholine receptor antibody titres in autoimmune myasthenia gravis after influenza vaccination (ProPATIent)
    Medical condition: Generalized Myasthenia gravis with positive antibodies against Acetylcholine-receptors (ICD10GM2006 G70.0)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003028-30 Sponsor Protocol Number: 808040019 Start Date*: 2015-11-02
    Sponsor Name:Technische Universität München, Fakultät für Medizin
    Full Title: Fr1da Insulin Intervention - Mechanistic study using oral insulin for immune and treatment efficacy in secondary prevention of type 1 diabetes
    Medical condition: Risk for type 1 diabetes
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002269-77 Sponsor Protocol Number: IM101611 Start Date*: 2017-08-07
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC with Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in ...
    Medical condition: Idiopathic Inflammatory Myopathy (IIM; eg, Dermatomyositis [DM], Polymyositis [PM], autoimmune necrotizing myopathy)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10042753 Symptomatic inflammatory myopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) SE (Completed) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000634-39 Sponsor Protocol Number: 808040006 Start Date*: 2007-09-03
    Sponsor Name:Forschergruppe Diabetes e. V. am Helmholtz Zentrum München
    Full Title: Postpartum Intervention in Women with Gestational Diabetes using Insulin
    Medical condition: women with a recent history of gestational diabetes which required insulin therapy up to 7 months post-partum
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002261-19 Sponsor Protocol Number: PRN1008-012 Start Date*: 2018-12-12
    Sponsor Name:Principia Biopharma
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor PRN1008 in Moderate to Severe Pemphigus
    Medical condition: pemphigus vulgaris [PV] or pemphigus foliaceus [PF]
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10052802 Pemphigus vulgaris LLT
    21.0 100000004858 10057054 Pemphigus foliaceous LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) ES (Ongoing) GR (Completed) HR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001852-41 Sponsor Protocol Number: GLP1-FMT Start Date*: 2022-09-06
    Sponsor Name:Radboud university medical center
    Full Title: BetaFIT study: Beta cell imaging after Faecal mIcrobiota Transplantation
    Medical condition: Type 1 diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005667-25 Sponsor Protocol Number: HGS1006-C1113 Start Date*: 2013-01-22
    Sponsor Name:GlaxoSmithKline, LLC
    Full Title: A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
    Medical condition: Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) CZ (Completed) EE (Completed) ES (Completed) IT (Completed) PT (Completed) BG (Completed) SK (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2019-003520-20 Sponsor Protocol Number: R668-BP-1902 Start Date*: 2020-05-19
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid
    Medical condition: Bullous pemphigoid (BP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10034277 Pemphigoid PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003755-64 Sponsor Protocol Number: DiAPREV/2014 Start Date*: 2014-11-13
    Sponsor Name:Helena Elding Larsson
    Full Title: A double-blind, randomized investigator-initiated study to determine the safety and the effect of Diamyd® in combination with Vitamin D on the progression to type 1 diabetes in children with multip...
    Medical condition: Children with HLA risk and persistent islet autoantibody positivity which is associated with a defined risk for type 1 diabetes
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000424-35 Sponsor Protocol Number: CLOU064A2302 Start Date*: 2021-11-04
    Sponsor Name:Novartis Pharma AG
    Full Title: A multicenter, randomized, double-blind, placebo-controlled Phase 3 study of remibrutinib (LOU064) to investigate the efficacy, safety and tolerability for 52 weeks in adult chronic spontaneous urt...
    Medical condition: Chronic Spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) DK (Completed) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 15:40:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA